Pegfilgrastim Biosimilars Market New Trends, Share Analysis And Forecast To 2033

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Pegfilgrastim Biosimilars Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The pegfilgrastim biosimilars market size has grown rapidly in recent years. It will grow from $1.59 billion in 2023 to $1.75 billion in 2024 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to increase in cancer prevalence, government initiatives, increased healthcare expenditure, increase in biopharmaceutical r&d expenditure, low cost of biosimilars, and high penetration of the biosimilar drugs.

The pegfilgrastim biosimilars market size is expected to see strong growth in the next few years. It will grow to $2.32 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing prevalence of cancer, aging population, increasing number of approvals, and targets and incentives . Major trends in the forecast period include taking advantage of the less stringent regulations to develop new and improved biosimilars, investing extensively in r&d activities for the development of effective and innovative biologics, focusing on establishing strategic partnerships with the large players to expand their research and developments activities in new drug developments and increasing their focus on m&a growth strategies to expand the customer base and their geographic markets, and increasing focus towards the production of biosimilars for neutropenia treatment to improve revenues and product offerings.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp

Market Segmentation:
The pegfilgrastim biosimilars market covered in this report is segmented -
1) By Application: Chemotherapy Treatment, Transplantation, Other Applications
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

Major Driver - Government Initiatives Drive Growth In Pegfilgrastim Biosimilars Market
Government initiatives for the development of biosimilars are expected to drive the pegfilgrastim biosimilars market. Governments worldwide are focusing on the development of biosimilars due to their cost-effective nature. The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan, to increase treatment options. The Australian government is committed to the Biosimilar Awareness Initiative, and they improved their commitment by supporting the Generic and Biosimilar Medicines Association through a grant of $5 million to accept increased general biosimilar education and activities that promote the suitable dispensing, prescription, and use of biosimilar medicines. Hence, the government initiatives for the development of biosimilars aid in the increased production and awareness that, in turn, support the growth of the pegfilgrastim biosimilars market.

Competitive Landscape:
Major companies operating in the pegfilgrastim biosimilars market report are Coherus BioSciences, Sandoz, Biocon/Mylan, Intas Biopharmaceuticals Ltd, Mundipharma GmbH, Dr. Reddy's Laboratories, Pfizer Inc., Emcure Pharmaceuticals, USV Private Limited, Apotex Pty Ltd, Kyowa Kirin Co. Ltd, Qilu Pharmaceutical, Gennova Biopharmaceuticals Limited, Lupin Limited, Coherus Biosciences Inc, Fresenius Kabi, Napp Pharmaceuticals, Boicon, Amega Biotech.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Top Trend - Strategic Collaborations Fueling New Launches In The Pegfilgrastim Biosimilar Market
Companies in the pegfilgrastim biosimilar market are increasing their product innovation through strategic collaborations. To sustain themselves in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with academic and research institutions in this market by way of partnerships or out-licensing deals, this trend has been increasing over the past few years. For instance, in May 2023, Amneal Pharmaceuticals, a US-based generics and specialty pharmaceutical company, partnered with Kashiv Biosciences, a US-based integrated biosciences company, to develop and introduce Fylnetra (pegfilgrastim-pbbk), a biosimilar pegfilgrastim. FYLNETRA is a preservative-free, clear solution offered in a 6 mg/0.6 mL single-dose prefilled syringe. It's used to reduce infection risks, specifically febrile neutropenia, in patients with non-myeloid cancers undergoing certain myelosuppressive anti-cancer treatments.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Pegfilgrastim Biosimilars Market Characteristics
3. Pegfilgrastim Biosimilars Market Trends And Strategies
4. Pegfilgrastim Biosimilars Market - Macro Economic Scenario
5. Pegfilgrastim Biosimilars Market Size And Growth
…..
27. Pegfilgrastim Biosimilars Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.